



SDI Review Form 1.6

Journal Name:	International Journal of TROPICAL DISEASE & Health
Manuscript Number:	Ms_IJTDH_26984
Title of the Manuscript:	Fecal calprotectin in assessment of ulcerative colitis activity
Type of the Article	Original

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	This is a nice article dealing with the use of calprotectine measurement in patients with active or inactive UC in comparison with other inflammatory indices including ESR and CRP. The article should be published, provided that authors should take into account the following remarks: The list of references is incomplete. There is a large number of recently published relevant studies that authors should refer and include in their paper. The first one is a metaanalysis published in 2014 which concluded: "The FC test is a reliable marker for assessing IBD disease activity and may have greater ability to evaluate disease activity in UC than CD". (Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, Nie B, Jiang B. <i>Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis.</i> 2014;20:1407-1415). There is also a number of other studies that came in the same conclusion. Here are the titles of these references 1. Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. <i>Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol.</i> 2016;16:47. 2. Brandse JF, Bennink RJ, van Eeden S, Löwenberg M, van den Brink GR, D'Haens GR. <i>Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Inflamm Bowel Dis.</i> 2016;22:1384-1390. 3. Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, Croitoru	



SDI Review Form 1.6

	<i>K, Van Assche G, Silverberg MS, Steinhart AH. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflamm Bowel Dis. 2016;22:623-630.</i> 4. <i>Yamaguchi S, Takeuchi Y, Arai K, Fukuda K, Kuroki Y, Asonuma K, Takahashi H, Saruta M, Yoshida H. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2016;31:93-98.</i> 5. <i>Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015;13:1929-36.e1.</i> 6. <i>Kennedy NA, Clark A, Walkden A, Chang JC, Fasci-Spurio F, Muscat M, Gordon BW, Kingstone K, Satsangi J, Arnott ID, Lees CW. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years. J Crohns Colitis. 2015;9:41-49.</i> 7. <i>Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:1042-1048.</i> The authors should clarify the exact hour of the day of fecal collection and the total time of storage of stool samples, as a great variability in the concentrations of calprotectin in stool samples collected during a single day has been observed (Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26-32. Finally the authors should comment on the relative small number of patients included in the study. Is it due to the low prevalence of disease in their country or something else?	
--	---	--



SDI Review Form 1.6

<u>Minor</u> REVISION comments	Some grammatical errors should be corrected	
<u>Optional/General</u> comments	This is an original article dealing with a subject recently being under intense investigation	

Reviewer Details:

Name:	John K. Triantafillidis
Department, University & Country	IASO General Hospital, Holargos, Athens, Greece